Relay Therapeutics, Inc. (RLAY)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Relay Therapeutics topped consensus EPS expectations in the third fiscal quarter of 2026, reported November 4, 2026, with EPS of -$0.37 topping the -$0.40 estimate by $0.03, based on preliminary results. The biotech posted a GAAP operating loss of roughly $90.2 million and a GAAP net loss of about $81.7 million, a net income result that was down 10.2% year over year from about -$74.1 million a year ago. Operating cash flow was negative at roughly $63.9 million as the company continued funding its oncology-focused small-molecule pipeline work, including programs such as RLY-4008, RLY-1971, and RLY-2608. For the next period, consensus calls for EPS of -$0.37 on revenue of $7.3 million.
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a NASDAQ-listed biotechnology company that develops small molecule therapies for cancer and genetic conditions through a precision-medicine approach and clinical trials. In FY2025, Relay Therapeutics generated $15.4 million in revenue. The company, formerly known as Allostery, Inc., is based in Cambridge, Massachusetts, was founded in 2015, and went public in 2020.
Today's Snapshot
The day ended with RLAY slightly higher at 16.51, while its sector was weaker. Relay Therapeutics advanced zovegalisib, an experimental cancer drug, toward pivotal trials.
Trading Volume
Below 10d avg (2.7M)
2.4M
vs S&P 500 Today
Outperforming Market
+0.50%
Updated: November 18, 2026 at 21:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$15.10 - $18.23Sell
- RSI (14)40.57Neutral
- Stochastic %K (14, 3, 3)8.25Buy
- MACD Level (12, 26)-0.24Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.